CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to develop interferon-beta as a treatment for acute lung injury and acute respiratory distress syndrome, conditions with high mortality rates. The research will involve clinical trials to assess safety and efficacy, aiming to provide a new pharmacological option for affected patients.
This application aims at a European marketing application for an orphan indication of the biopharmaceutical interferon-beta (IFN-beta) (EU3/07/505), to treat acute lunge injury (ALI) and acute respiratory distress syndrome (ARDS).
Despite the much improved mechanical ventilation techniques and improved supportive therapies, ARDS kills 35-40 % of the 175.000 annual European patients.
This condition has no approved pharmacological treatment in Europe.
The applicant, Faron Pharmaceuticals, has rece…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Torino
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Finland, Turku
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Roma
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
